Table 1.
Nucleotide mutations and amino acid substitutions in the studied samples.
|
Region |
5UTR |
VP3 |
VP1 |
2A |
2B |
2C |
3C |
3D |
|||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Position in genome | 109 | 615 | 1914 | 2004 | 2332 | 3040 | 3556 | 3575 | 3850 | 4098 | 4916 | 5739 | 6876 |
| Placebo (Day 4) | T | C | T | A | G | A | C | A | T | C | G | T | C |
| PMO (Day 13) | T | T | T | A | G | A | T | A | C | C | G | T | C |
| P→Sa | |||||||||||||
| Pleconaril (Day 13) | C | C | C | A | G | A | C | G | T | T | G | C | C |
| H→Ra | |||||||||||||
| MDL-860 (Day 7) | T | C | T | T | A | A | C | A | T | C | A | T | C |
| V→Ia | R→Ka | ||||||||||||
| Oxoglaucine (Day 4) | T | C | T | A | G | T | C | A | T | C | G | T | T |
| T→Sa | |||||||||||||
aAmino acid substitution.
PMO: pleconaril/MDL-860/oxoglaucine.